Chinese generic company takes another step along the road to becoming a full-blown originator
China’s Shanghai Fosun Pharmaceutical has announced a cooperation agreement with Switzerland-based biopharmaceutical and research company Sellas Life Sciences Group for the licensing of $533 million worth of IP rights relating to diabetes and cancer…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now